GKB (1707) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 葡萄王

GKB (1707) reported revenue of NT$748.3 million for Oct 2026, -30.8% year on year and +3.0% from the previous month. Revenue for Jan–Oct 2026 was NT$7.59 billion (-8.9% year on year).

In Oct 2026, it ranked No. 9 by revenue among 160 Biotech & Medical companies.

Next ex-date: 2026-12-30 (Cash dividend, cash per share NT$1.9) Taiwan ex-dividend calendar →

Monthly revenue chart

Oct 2024 NT$879.1 million24/10Nov 2024 NT$1.08 billionDec 2024 NT$1.19 billionJan 2025 NT$696.1 millionFeb 2025 NT$634.3 million25/02Mar 2025 NT$921.8 millionApr 2025 NT$858 millionMay 2025 NT$827.4 millionJun 2025 NT$883.6 million25/06Jul 2025 NT$755 millionAug 2025 NT$884.1 millionSep 2025 NT$788.7 millionOct 2025 NT$1.08 billion25/10Nov 2025 NT$1.09 billionDec 2025 NT$829.4 millionJan 2026 NT$794.5 millionFeb 2026 NT$625.8 million26/02Mar 2026 NT$857.7 millionApr 2026 NT$806.4 millionMay 2026 NT$787.6 millionJun 2026 NT$819.6 million26/06Jul 2026 NT$716.7 millionAug 2026 NT$706.1 millionSep 2026 NT$726.3 millionOct 2026 NT$748.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$748.3 million-30.8%+3.0%
Sep 2026NT$726.3 million-7.9%+2.9%
Aug 2026NT$706.1 million-20.1%-1.5%
Jul 2026NT$716.7 million-5.1%-12.6%
Jun 2026NT$819.6 million-7.2%+4.1%
May 2026NT$787.6 million-4.8%-2.3%
Apr 2026NT$806.4 million-6.0%-6.0%
Mar 2026NT$857.7 million-7.0%+37.1%
Feb 2026NT$625.8 million-1.3%-21.2%
Jan 2026NT$794.5 million+14.1%-4.2%
Dec 2025NT$829.4 million-30.4%-24.1%
Nov 2025NT$1.09 billion+0.8%+1.0%
Oct 2025NT$1.08 billion+22.9%+37.0%
Sep 2025NT$788.7 million-36.0%-10.8%
Aug 2025NT$884.1 million+5.4%+17.1%
Jul 2025NT$755 million-8.8%-14.6%
Jun 2025NT$883.6 million+0.0%+6.8%
May 2025NT$827.4 million-13.0%-3.6%
Apr 2025NT$858 million-7.2%-6.9%
Mar 2025NT$921.8 million-3.9%+45.3%
Feb 2025NT$634.3 million+6.0%-8.9%
Jan 2025NT$696.1 million-11.8%-41.6%
Dec 2024NT$1.19 billion-0.5%+10.0%
Nov 2024NT$1.08 billion-8.3%+23.3%
Oct 2024NT$879.1 million+7.0%-28.7%

Jan–Oct 2026 cumulative: NT$7.59 billion (-8.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: GKB vs PEC / GKB vs Lotus Pharm / GKB vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16